Three-Year Overall Survival Outcomes and Correlative Analyses in Patients with NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated with First-Line Pembrolizumab or Cemiplimab
JTO clinical and research reports（2024）
Key words
PD-L1,Cemiplimab,Pembrolizumab,Long-term outcomes,Biomarkers
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined